药物可以提高速度,反应时间和运动时间,但不能提高幅度或在帕金森病的记忆引导达到过程中的错误
Michael P Trevarrow1, Miranda J Munoz1, Yessenia M Rivera1
1Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, Illinois, USA.
Physiological reports
|August 29, 2024
概括
抗帕金森药物改善了帕金森病 (PD) 患者在记忆引导任务期间的运动速度和反应时间. 然而,药物没有影响运动的精度或幅度,这表明对某些运动控制方面有特定的好处.
科学领域:
- 神经科学是一个神经科学.
- 发动机控制器的控制器
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 显著损害了运动控制,特别是在记忆引导的运动中.
- 抗帕金森症药物对这些特定运动缺陷的确切影响尚不清楚.
研究的目的:
- 为了研究抗帕金森症药物对PD患者在记忆引导的达到任务期间的运动控制的影响.
- 为了比较患有PD的参与者的表现,无论是服用药物还是不服用药物,与年龄相匹配的健康对照 (HC).
主要方法:
- 32名患有PD的参与者和13名HC参与者执行了记忆引导的达到任务,记忆延迟短 (0.5s) 和长 (5s).
- 患有PD的参与者在服用和停用抗帕金森药物时均被评估.
- 运动障碍学会统一帕金森病评分表 (MDS-UPDRS III) 的运动部分进行了管理.
主要成果:
- 抗帕金森药物增加了运动速度和振幅,并减少了PD参与者的运动时间和反应时间,使他们更接近HC性能.
- 药物治疗没有显著改变运动幅度或达到误差.
- 较短的保留延迟通常改善了运动速度,振幅和时间,同时增加了PD和HC组的反应时间.
结论:
- 抗帕金森症药物主要有利于PD患者在记忆引导任务期间的运动速度和反应时间.
- 药物对运动幅度和精度的影响是有限的.
- 这些发现突显了抗帕金森药物在运动控制中的特定神经生理机制.
相关概念视频
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
01:15Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
281
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
281
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
49
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
49
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
104
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
104